Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Chronic low back pain is a common and disabling condition that affects millions of people in the United States. Many people with chronic low back pain do not get enough relief from current treatments. Cannabis may help reduce pain, but researchers do not fully understand how it affects the brain in people with chronic pain. The purpose of this study is to examine how inhaled cannabis changes brain activity and reduces pain in people with chronic low back pain. Results from this study may help researchers better understand how cannabis works for pain and support the development of improved pain treatments.
Chronic low back pain is one of the most common causes of pain and disability in adults. Unfortunately, treatments that can directly reduce chronic low back pain remain limited. Cannabis has shown promise for pain relief, but researchers do not yet fully understand how it affects the brain or reduces pain in people with chronic pain.
The purpose of this study is to examine how inhaled (vaporized, not smoked) cannabis affects pain responses and brain activity in adults with chronic low back pain. Researchers will compare the effects of cannabis containing tetrahydrocannabinol (THC) to a placebo cannabis containing 0% THC.
This study involves one visit to the Keck Center for Functional MRI at UC San Diego. Participants will complete screening procedures, questionnaires, and pain testing using heat stimulation applied to the calf. Participants will be trained to rate their pain intensity and unpleasantness. A straight leg raise maneuver will also be performed to assess low back pain and any pain radiating down the leg.
Participants will inhale either THC-containing cannabis or placebo cannabis (no THC) using a vaporization device under study staff supervision. Brain imaging, heat pain testing, leg raise assessments, and pain ratings will be collected before and after cannabis administration to evaluate changes in pain processing and brain activity. Researchers will also assess self-reported pain, mood, sleep, stress, and cannabis-related effects using standardized questionnaires.
This study may improve understanding of how cannabis influences the brain and pain systems in people with chronic low back pain, and findings may help support the development of improved treatments for chronic pain.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active THC | Experimental | Participants will be administered 400mg of vaporized cannabis (5.1%) before pain testing and fMRI. |
|
| Placebo THC | Placebo Comparator | Participants will be administered 400mg of vaporized cannabis (<.1%) before pain testing and fMRI. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Active Cannabis | Drug | 400 mg of vaporized and inhaled active cannabis (5.1%) |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Cerebral Blood Flow (CBF) | Changes in brain blood flow and oxygen levels will be measured using non-invasive MRI-based brain imaging methods. These scans will assess how much blood is reaching brain tissue and how oxygen levels in the brain change over time. | All data will be collected at the single study session (Day 1). |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Ratings | Pain ratings will be assessed in response to noxious heat stimulation. Pain intensity and pain unpleasantness will be measured using a 0-10 Visual Analog Scale (VAS), where 0 indicates "no pain" and 10 indicates "most intense imaginable pain" or "most unpleasant imaginable pain." Higher scores indicate greater pain intensity or unpleasantness. Subjective response to cannabis will be assessed using a 0-10 Numeric Rating Scale (NRS), with higher scores indicating greater subjective effects. |
| Measure | Description | Time Frame |
|---|---|---|
| Neurochemical Metabolites | We will use a specialized, non-invasive brain scan called proton magnetic resonance spectroscopy (1H-MRS) to measure certain brain chemicals linked to pain processing, including glutamate, GABA, and myo-inositol. The scan uses radiofrequency signals (sim | All data will be collected at the single study session (Day 1). |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Madelynn Meredith, BS | Contact | 619-431-1850 | mameredith@health.ucsd.edu | |
| Yasmeen Esshaki, MA | Contact | 619-786-0375 | yesshaki@health.ucsd.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for Functional MRI - W.M.Keck Building | Recruiting | La Jolla | California | 92093 | United States |
Not provided
| ID | Term |
|---|---|
| D012585 | Sciatica |
| D011843 | Radiculopathy |
| D017116 | Low Back Pain |
| D055959 | Intervertebral Disc Degeneration |
| D001416 | Back Pain |
| D002189 | Marijuana Abuse |
| ID | Term |
|---|---|
| D020426 | Sciatic Neuropathy |
| D020422 | Mononeuropathies |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Participants and outcome assessor will not be made aware if they are receiving active or placebo marijuana.
| Placebo Cannabis |
| Drug |
400 mg of vaporized and inhaled placebo cannabis (<.1%) |
|
|
| All data will be collected at the single study session (Day 1). |
| Respiration Rate |
Changes in breathing rate may be associated with pain relief and improved well-being. Breathing rate will be monitored continuously in real time to ensure accurate data collection. |
| All data will be collected at the single study session (Day 1). |
| THC Concentrations | THC concentrations will be measured to evaluate the relationship between THC levels and pain relief. | All data will be collected at the single study session (Day 1). |
| D009422 | Nervous System Diseases |
| D009437 | Neuralgia |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |